Avicena Group, Inc. is a late stage biotechnology company focused on developing products based on its proprietary understanding of the regulation of cellular energy processes. The company's core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). The company is currently analyzing data from its Phase IIb/III trial in ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease). Avicenaís HD-02 is being studied in Phase III clinical trials in both Huntingtonís disease and in Parkinsonís disease. Avicena's science is well established and its products are safe and well tolerated. Unlike traditional biotechnology companies, Avicena's clinical programs are largely funded by government and non-profit organizations. Avicena presently derives revenue from the sale of proprietary ingredients to skin care manufacturers.
Additionally, the company is also investigating certain other therapies for Creatine Transporter Defect, Charcot-Marie-Tooth Syndrome and Duchenne Muscular Dystrophy.
With regard to the OTC market, the company is developing novel products focused on the high-growth dermaceutical and nutraceutical areas. As with its pharmaceutical candidates, these OTC products leverage the company's in-depth understanding of the critical role of cellular energy in the body.